Abstract:Depression is one of the complications in patients with polycystic ovary syndrome (PCOS) that leads to considerable mental health. Accumulating evidence suggests that human gut microbiomes are associated with the progression of PCOS and depression. However, whether microbiota influences depression development in PCOS patients is still uncharacterized. In this study, we employed metagenomic sequencing and transcriptome sequencing (RNA-seq) to profile the composition of the fecal microbiota and gene expression of peripheral blood mononuclear cells in depressed women with PCOS (PCOS-DP, n = 27) in comparison to mentally healthy women with PCOS (PCOS, n = 18) and compared with healthy control (HC, n = 27) and patients with major depressive disorder (MDD, n = 29). Gut microbiota assessment revealed distinct patterns in the relative abundance in the PCOS-DP compared to HC, MDD, and PCOS groups. Several gut microbes exhibited uniquely and significantly higher abundance in the PCOS-DP compared to PCOS patients, inducing EC Ruminococcus torques, Coprococcus comes, Megasphaera elsdenii, Acidaminococcus intestini, and Barnesiella viscericola. Bacteroides eggerthii was a potential gut microbial biomarker for the PCOS-DP. RNA-seq profiling identified that 35 and 37 genes were significantly elevated and downregulated in the PCOS-DP, respectively. The enhanced differential expressed genes (DEGs) in the PCOS-DP were enriched in pathways involved in signal transduction and endocrine and metabolic diseases, whereas several lipid metabolism pathways were downregulated. Intriguingly, genes correlated with the gut microbiota were found to be significantly enriched in pathways of neurodegenerative diseases and the immune system, suggesting that changes in the microbiota may have a systemic impact on the expression of neurodegenerative diseases and immune genes. Gut microbe-related DEGs of CREB3L3 and CCDC173 were possible molecular biomarkers and therapeutic targets of women with PCOS-DP. Our multi-omics data indicate shifts in the gut microbiome and host gene regulation in PCOS patients with depression, which is of possible etiological and diagnostic importance.

Proteomic Profiling Reveals Microbiota-Driven Sensing Mechanisms of Gut-Brain Axis in Depression

Proteomics analysis of the gut–brain axis in a gut microbiota-dysbiosis model of depression

Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression

Microbiota Alters and Its Correlation with Molecular Regulation Underlying Depression in PCOS Patients

Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder.

Integrated Phosphoproteomic and Metabolomic Profiling Reveals Perturbed Pathways in the Hippocampus of Gut Microbiota Dysbiosis Mice

Gut Microbiome Remodeling Induces Depressive-Like Behaviors Through A Pathway Mediated by the Host'S Metabolism

Characteristics of gut microbiota and metabolic phenotype in patients with major depressive disorder based on multi-omics analysis

A pilot exploration of multi-omics research of gut microbiome in major depressive disorders

Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism

Microbiome and tryptophan metabolomics analysis in adolescent depression: roles of the gut microbiota in the regulation of tryptophan-derived neurotransmitters and behaviors in human and mice

Altered gut bacterial-fungal interkingdom networks in children and adolescents with depression

Integrated multi-omics analysis reveals gut microbiota dysbiosis and systemic disturbance in major depressive disorder

Metabolite identification in fecal microbiota transplantation mouse livers and combined proteomics with chronic unpredictive mild stress mouse livers

Associations Between Disordered Microbial Metabolites and Changes of Neurotransmitters in Depressed Mice.

Variations in Gut Microbiota and Fecal Metabolic Phenotype Associated with Depression by 16S Rrna Gene Sequencing and LC/MS-based Metabolomics.

Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder

Deciphering the Gut Microbiome's Influence on Depression: A Community-Level Constraint-Based Metabolic modelling Approach

Multi-omics data reveals the important role of glycerophospholipid metabolism in the crosstalk between gut and brain in depression

Relationships between the gut microbiome and brain functional alterations in first-episode, drug-naïve patients with major depressive disorder

Associations between disordered gut microbiota and changes of neurotransmitters and short-chain fatty acids in depressed mice